Dianna Shipley
About
Dianna Shipley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Dianna Shipley has authored 68 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Dianna Shipley's work include Lung Cancer Treatments and Mutations (19 papers), Cancer Treatment and Pharmacology (18 papers) and Lung Cancer Research Studies (13 papers). Dianna Shipley is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Cancer Treatment and Pharmacology (18 papers) and Lung Cancer Research Studies (13 papers). Dianna Shipley collaborates with scholars based in United States and United Kingdom. Dianna Shipley's co-authors include John D. Hainsworth, F. Anthony Greco, David R. Spigel, Howard A. Burris, Dana S. Thompson, David Waterhouse, C. Farley, Denise A. Yardley, John H. Barton and Robert C. Whorf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Dianna Shipley
67 papers receiving 1.1k citations
Peers
Dianna Shipley
John H. Barton United States
Frank Priou France
Eiichi Sasaki Japan
Paul Richards United States
Marius Lund‐Iversen Norway
Hui‐Lan Rao China
Priyanka Shivdasani United States
Yasir Y. Elamin United States
Vicki L. Keedy United States
J.P. Delord France
Citations per year, relative to Dianna Shipley Dianna Shipley (= 1×)
peers
John H. Barton
Countries citing papers authored by Dianna Shipley
Since
Specialization
Citations
This map shows the geographic impact of Dianna Shipley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dianna Shipley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dianna Shipley more than expected).
Fields of papers citing papers by Dianna Shipley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dianna Shipley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dianna Shipley. The network helps show where Dianna Shipley may publish in the future.
Co-authorship network of co-authors of Dianna Shipley
This figure shows the co-authorship network connecting the top 25 collaborators of Dianna Shipley. A scholar is included among the top collaborators of Dianna Shipley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dianna Shipley. Dianna Shipley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yardley, Denise A., Dianna Shipley, Patrick J. Ward, et al.. (2018). A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. Clinical Breast Cancer. 19(1). 1–9.
2.
Spigel, David R., Mark S. Rubin, Victor G. Gian, et al.. (2017). Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. 113. 79–84.
3.
Yardley, Denise A., Dianna Shipley, N. W. Peacock, et al.. (2015). Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 152(3). 557–567.
4.
Hainsworth, John D., et al.. (2013). High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Genitourinary Cancer. 11(3). 283–289.e1.
5.
Hainsworth, John D., David Waterhouse, Dianna Shipley, et al.. (2013). Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium. Cancer Investigation. 31(5). 323–329.
6.
Spigel, David R., F. Anthony Greco, David Waterhouse, et al.. (2012). Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer. 78(1). 70–75.
7.
Gian, Victor G., Mark S. Rubin, Dianna Shipley, et al.. (2012). Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 7587–7587.
8.
Yardley, Denise A., Howard A. Burris, Bobby L. Clark, et al.. (2011). Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Breast Cancer. 11(3). 146–152.
9.
Spigel, David R., F. Anthony Greco, Howard A. Burris, et al.. (2011). A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 12(3). 187–191.
10.
Spigel, David R., Johanna C. Bendell, Michael McCleod, et al.. (2011). Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer. Clinical Colorectal Cancer. 11(1). 45–52.
11.
Burris, Howard A., Suzanne F. Jones, Dianna Shipley, et al.. (2010). Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer. Cancer Investigation. 28(4). 408–412.
12.
Yardley, Denise A., Howard A. Burris, N. W. Peacock, et al.. (2010). A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123(2). 471–475.
13.
Hainsworth, John D., David R. Spigel, Bobby L. Clark, et al.. (2010). Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site. The Cancer Journal. 16(1). 70–75.
14.
Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2009). Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer. 115(10). 2138–2146.
15.
Yardley, Denise A., Howard A. Burris, David R. Spigel, et al.. (2009). A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer. Clinical Breast Cancer. 9(4). 247–252.
16.
Hainsworth, John D., David R. Spigel, Tiffanie Markus, et al.. (2009). Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma & Myeloma. 9(3). 223–228.
17.
Jones, Suzanne F., Dana S. Thompson, John H. Barton, et al.. (2008). A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 9(3). 154–159.
18.
Yardley, Denise A., Howard A. Burris, Lisa Simons, et al.. (2008). A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 8(5). 425–431.
19.
Greco, F. Anthony, David R. Spigel, Dianna Shipley, et al.. (2007). Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network. Clinical Lung Cancer. 8(8). 483–487.
20.
Murphy, Patrick B., John D. Hainsworth, David R. Spigel, et al.. (2006). Topotecan—Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 24(18_suppl). 17000–17000.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John H. Barton Breakdown of academic impact, for papers by Frank Priou Breakdown of academic impact, for papers by Eiichi Sasaki Breakdown of academic impact, for papers by Paul Richards Breakdown of academic impact, for papers by Marius Lund‐Iversen Breakdown of academic impact, for papers by Hui‐Lan Rao Breakdown of academic impact, for papers by Priyanka Shivdasani Breakdown of academic impact, for papers by Yasir Y. Elamin Breakdown of academic impact, for papers by Vicki L. Keedy Breakdown of academic impact, for papers by J.P. Delord